ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 0843

Prevalence and Trends of Infections in Hospitalized Patients with Rheumatoid Arthritis in the United States

Pushti Khandwala1, Anila Hussain2 and Devashish Desai1, 1Crozer Chester Medical Center, Glen Mills, PA, 2Crozer Chester Medical Center, Glen Mills

Meeting: ACR Convergence 2021

Keywords: Infection, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 7, 2021

Session Title: RA – Treatments Poster I: Comparative Effectiveness, Biosimilars, Withdrawal, & the Real World (0813–0845)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: Rheumatoid arthritis (RA) patients have a higher risk of developing infections as compared to the patients without the diagnosis, and this risk is further augmented by the use of biologics and immunosuppressant medications used for the treatment. This could be explained by the disease process itself, associated comorbidities, and immunomodulation as a result of the treatment modalities. We aim to identify national trends in terms of the common infectious etiologies in RA patients leading to hospitalizations in the patients admitted within a 15 year time period.

Methods: We used the Nationwide Inpatient Sample (NIS) database (years 1999-2014) and extracted all patients with Rheumatoid Arthritis using validated International Classification of Disease (ICD) codes. Further, six common hospitalized infections were identified: Urinary tract infection (UTI), Pneumonia, Skin and soft tissue infection (SSTI), Sepsis, Bacteremia, and Opportunistic infections. Data was analyzed using Statistical Analysis System (SAS) 9.4 software.

Results: A total of 1,351,284 cases of Rheumatoid arthritis were identified in the 15 year period (1999-2014). Mean age was 66.55 ± 15.34 years with females making up 74.95% (n= 1,012,532) of the patient population. As seen in Figure 1, an overall upward trend was noticed in all 6 selected infections (p< 0.001). It was found that UTI was the most prevalent infection in this population, which was on the rise from 10.38% in 1999 to 15.15% in 2011, with a steady decline to 14.74% in 2014, followed by Pneumonia (9.6% in 1999, 11.67% in 2014). Sepsis (3.34% in 2006 to 9.51% in 2014) and Bacteremia (3.91% in 2006 to 9.48% in 2014) had a dramatic increase since 2006.

Length of stay (LOS) in RA patients without any infection is 4.43 days and the average cost is $29,833.65 whereas in RA patients with any of the infections, LOS increases to 6.95 days and the average cost is $39,214.49.

Conclusion: The use of biological agents for the treatment of RA is associated with improved outcomes by decreasing inflammation and improving the overall mortality and morbidity in RA patients. However, at the same time, this has led to a higher rate of infections as a result of immune suppression in RA patients. It has been reported that tumor necrosis (TNF) inhibitors are associated with a higher rate of infection when compared to conventional disease modifying agents, especially UTI, pneumonia and SSTI. In our study, we noticed that the common infections in hospitalized patients with RA included UTI and Pneumonia, both of which have risen since 1999. Higher UTI prevalence can also be explained by the female predominance. An increase in Sepsis was also seen which could be attributed to a higher infection rate, but maybe overestimated or correctly estimated as compared to past secondary to better coding and documentation of sepsis. Higher infection rates also contributed to longer hospital stays, thus leading to higher costs of care in these patients. Thus, there needs to be increased infection surveillance in this patient population, especially with the increasing use of biologic agents.

Figure 1: Trend of Infections over 15 years


Disclosures: P. Khandwala, None; A. Hussain, None; D. Desai, None.

To cite this abstract in AMA style:

Khandwala P, Hussain A, Desai D. Prevalence and Trends of Infections in Hospitalized Patients with Rheumatoid Arthritis in the United States [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/prevalence-and-trends-of-infections-in-hospitalized-patients-with-rheumatoid-arthritis-in-the-united-states/. Accessed January 30, 2023.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-and-trends-of-infections-in-hospitalized-patients-with-rheumatoid-arthritis-in-the-united-states/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences